210 related articles for article (PubMed ID: 31173157)
21. Gentiopicroside inhibits RANKL-induced osteoclastogenesis by regulating NF-κB and JNK signaling pathways.
Chen F; Xie L; Kang R; Deng R; Xi Z; Sun D; Zhu J; Wang L
Biomed Pharmacother; 2018 Apr; 100():142-146. PubMed ID: 29428661
[TBL] [Abstract][Full Text] [Related]
22. Constant hypoxia inhibits osteoclast differentiation and bone resorption by regulating phosphorylation of JNK and IκBα.
Ma Z; Yu R; Zhao J; Sun L; Jian L; Li C; Liu X
Inflamm Res; 2019 Feb; 68(2):157-166. PubMed ID: 30604211
[TBL] [Abstract][Full Text] [Related]
23. Magnolol prevents ovariectomy‑induced bone loss by suppressing osteoclastogenesis via inhibition of the nuclear factor‑κB and mitogen‑activated protein kinase pathways.
Fei WY; Huo Q; Zhao PQ; Qin LJ; Li T
Int J Mol Med; 2019 Apr; 43(4):1669-1678. PubMed ID: 30816431
[TBL] [Abstract][Full Text] [Related]
24. [Zoledronate regulates osteoclast differentiation and bone resorption in high glucose through p38 MAPK pathway].
Lin Y; Gu Y; Zuo G; Jia S; Liang Y; Qi M; Dong W
Nan Fang Yi Ke Da Xue Xue Bao; 2020 Oct; 40(10):1439-1447. PubMed ID: 33118518
[TBL] [Abstract][Full Text] [Related]
25. Aconine inhibits RANKL-induced osteoclast differentiation in RAW264.7 cells by suppressing NF-κB and NFATc1 activation and DC-STAMP expression.
Zeng XZ; He LG; Wang S; Wang K; Zhang YY; Tao L; Li XJ; Liu SW
Acta Pharmacol Sin; 2016 Feb; 37(2):255-63. PubMed ID: 26592521
[TBL] [Abstract][Full Text] [Related]
26. Herbacetin inhibits RANKL-mediated osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
Li L; Sapkota M; Kim SW; Soh Y
Eur J Pharmacol; 2016 Apr; 777():17-25. PubMed ID: 26923730
[TBL] [Abstract][Full Text] [Related]
27. Leonurine hydrochloride inhibits osteoclastogenesis and prevents osteoporosis associated with estrogen deficiency by inhibiting the NF-κB and PI3K/Akt signaling pathways.
Yuan FL; Xu RS; Jiang DL; He XL; Su Q; Jin C; Li X
Bone; 2015 Jun; 75():128-37. PubMed ID: 25708053
[TBL] [Abstract][Full Text] [Related]
28. Proanthocyanidins inhibit osteoclast formation and function by inhibiting the NF-κB and JNK signaling pathways during osteoporosis treatment.
Zhu W; Yin Z; Zhang Q; Guo S; Shen Y; Liu T; Liu B; Wan L; Li S; Chen X; Ouyang Z; Peng D
Biochem Biophys Res Commun; 2019 Jan; 509(1):294-300. PubMed ID: 30583865
[TBL] [Abstract][Full Text] [Related]
29. AP-002: A novel inhibitor of osteoclast differentiation and function without disruption of osteogenesis.
Wang Y; Mei Y; Song Y; Bachus C; Sun C; Sheshbaradaran H; Glogauer M
Eur J Pharmacol; 2020 Dec; 889():173613. PubMed ID: 33007291
[TBL] [Abstract][Full Text] [Related]
30. The polymethoxy flavonoid sudachitin suppresses inflammatory bone destruction by directly inhibiting osteoclastogenesis due to reduced ROS production and MAPK activation in osteoclast precursors.
Ohyama Y; Ito J; Kitano VJ; Shimada J; Hakeda Y
PLoS One; 2018; 13(1):e0191192. PubMed ID: 29342179
[TBL] [Abstract][Full Text] [Related]
31. Icariin abrogates osteoclast formation through the regulation of the RANKL-mediated TRAF6/NF-κB/ERK signaling pathway in Raw264.7 cells.
Kim B; Lee KY; Park B
Phytomedicine; 2018 Dec; 51():181-190. PubMed ID: 30466615
[TBL] [Abstract][Full Text] [Related]
32. Adiponectin inhibits osteoclastogenesis by suppressing NF-κB and p38 signaling pathways.
Chen G; Huang L; Wu X; Liu X; Xu Q; Li F; Dai M; Zhang B
Biochem Biophys Res Commun; 2018 Sep; 503(3):2075-2082. PubMed ID: 30107914
[TBL] [Abstract][Full Text] [Related]
33. Echinocystic acid inhibits RANKL-induced osteoclastogenesis by regulating NF-κB and ERK signaling pathways.
Yang JH; Li B; Wu Q; Lv JG; Nie HY
Biochem Biophys Res Commun; 2016 Sep; 477(4):673-677. PubMed ID: 27349866
[TBL] [Abstract][Full Text] [Related]
34. Picroside II Inhibits RANKL-Mediated Osteoclastogenesis by Attenuating the NF-κB and MAPKs Signaling Pathway In Vitro and Prevents Bone Loss in Lipopolysaccharide Treatment Mice.
Yang X; Gao W; Wang B; Wang X; Guo H; Xiao Y; Kong L; Hao D
J Cell Biochem; 2017 Dec; 118(12):4479-4486. PubMed ID: 28464271
[TBL] [Abstract][Full Text] [Related]
35. Salicortin inhibits osteoclast differentiation and bone resorption by down-regulating JNK and NF-κB/NFATc1 signaling pathways.
Nie S; Xu J; Zhang C; Xu C; Liu M; Yu D
Biochem Biophys Res Commun; 2016 Jan; 470(1):61-67. PubMed ID: 26740180
[TBL] [Abstract][Full Text] [Related]
36. Curcumin (diferuloylmethane) inhibits receptor activator of NF-kappa B ligand-induced NF-kappa B activation in osteoclast precursors and suppresses osteoclastogenesis.
Bharti AC; Takada Y; Aggarwal BB
J Immunol; 2004 May; 172(10):5940-7. PubMed ID: 15128775
[TBL] [Abstract][Full Text] [Related]
37. Longan fruit increase bone mineral density in zebrafish and ovariectomized rat by suppressing RANKL-induced osteoclast differentiation.
Son Y; Lee EM; Lee DY; Lee JH; Oh S
Phytomedicine; 2019 Jun; 59():152910. PubMed ID: 30978650
[TBL] [Abstract][Full Text] [Related]
38. Poligoni Multiflori Radix enhances osteoblast formation and reduces osteoclast differentiation.
Han SY; Lee KH; Kim YK
Int J Mol Med; 2018 Jul; 42(1):331-345. PubMed ID: 29620250
[TBL] [Abstract][Full Text] [Related]
39. α-Linolenic Acid Inhibits Receptor Activator of NF-κB Ligand Induced (RANKL-Induced) Osteoclastogenesis and Prevents Inflammatory Bone Loss via Downregulation of Nuclear Factor-KappaB-Inducible Nitric Oxide Synthases (NF-κB-iNOS) Signaling Pathways.
Song J; Jing Z; Hu W; Yu J; Cui X
Med Sci Monit; 2017 Oct; 23():5056-5069. PubMed ID: 29061958
[TBL] [Abstract][Full Text] [Related]
40. Thymoquinone prevents RANKL-induced osteoclastogenesis activation and osteolysis in an in vivo model of inflammation by suppressing NF-KB and MAPK Signalling.
Thummuri D; Jeengar MK; Shrivastava S; Nemani H; Ramavat RN; Chaudhari P; Naidu VG
Pharmacol Res; 2015 Sep; 99():63-73. PubMed ID: 26022736
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
